var data={"title":"Treatment protocols for lymphoma","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment protocols for lymphoma</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-lymphoma/contributors\" class=\"contributor contributor_credentials\">Tim Brenner, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-lymphoma/contributors\" class=\"contributor contributor_credentials\">Shrina Duggal, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-lymphoma/contributors\" class=\"contributor contributor_credentials\">Jim Natale, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-lymphoma/contributors\" class=\"contributor contributor_credentials\">Scott M Wirth, PharmD, BCOP</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-lymphoma/contributors\" class=\"contributor contributor_credentials\">John W Mucenski, PharmD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-lymphoma/contributors\" class=\"contributor contributor_credentials\">Alan G Rosmarin, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-lymphoma/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 14, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H4993771\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with lymphoma. <strong>This is</strong> <strong>not an exhaustive list</strong>; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with lymphoma. Additional regimens may be added over time, particularly as treatment for lymphoma evolves.</p><p>This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with lymphoma. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=initial-treatment-of-limited-stage-diffuse-large-b-cell-lymphoma\" class=\"medical medical_review\">&quot;Initial treatment of limited stage diffuse large B cell lymphoma&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=initial-treatment-of-advanced-stage-diffuse-large-b-cell-lymphoma\" class=\"medical medical_review\">&quot;Initial treatment of advanced stage diffuse large B cell lymphoma&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma\" class=\"medical medical_review\">&quot;Treatment of relapsed or refractory diffuse large B cell lymphoma&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=initial-treatment-of-limited-stage-i-ii-follicular-lymphoma\" class=\"medical medical_review\">&quot;Initial treatment of limited stage (I/II) follicular lymphoma&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=initial-treatment-of-advanced-stage-iii-iv-follicular-lymphoma\" class=\"medical medical_review\">&quot;Initial treatment of advanced stage (III/IV) follicular lymphoma&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-follicular-lymphoma\" class=\"medical medical_review\">&quot;Treatment of relapsed or refractory follicular lymphoma&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=overview-of-the-treatment-of-classical-hodgkin-lymphoma-in-adults\" class=\"medical medical_review\">&quot;Overview of the treatment of classical Hodgkin lymphoma in adults&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=initial-treatment-of-peripheral-t-cell-lymphoma\" class=\"medical medical_review\">&quot;Initial treatment of peripheral T cell lymphoma&quot;</a>.)</p><p/><p>These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</p><p class=\"headingAnchor\" id=\"H4993783\"><span class=\"h1\">REGIMENS</span></p><p class=\"headingAnchor\" id=\"H4994024\"><span class=\"h2\">Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone with 21 days between cycles (R-CHOP-21)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F63586\" class=\"graphic graphic_table graphicRef63586 \">table 1</a>)</p><p class=\"headingAnchor\" id=\"H4994079\"><span class=\"h2\">Rituximab plus ifosfamide, carboplatin, and etoposide (R-ICE)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F76030\" class=\"graphic graphic_table graphicRef76030 \">table 2</a>)</p><p class=\"headingAnchor\" id=\"H935886705\"><span class=\"h2\">Cyclophosphamide plus doxorubicin, vincristine, and prednisone with 21 days between cycles (CHOP-21)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F81762\" class=\"graphic graphic_table graphicRef81762 \">table 3</a>)</p><p class=\"headingAnchor\" id=\"H935886730\"><span class=\"h2\">Doxorubicin plus bleomycin, vinblastine, and dacarbazine (ABVD)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F68131\" class=\"graphic graphic_table graphicRef68131 \">table 4</a>)</p><p class=\"headingAnchor\" id=\"H4149304156\"><span class=\"h2\">Bendamustine plus rituximab (BR)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F111141\" class=\"graphic graphic_table graphicRef111141 \">table 5</a>)</p><p class=\"headingAnchor\" id=\"H546943109\"><span class=\"h2\">Fludarabine plus rituximab (FR)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F86798\" class=\"graphic graphic_table graphicRef86798 \">table 6</a>)</p><p class=\"headingAnchor\" id=\"H546943159\"><span class=\"h2\">Fludarabine, cyclophosphamide, and rituximab (FCR)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F86797\" class=\"graphic graphic_table graphicRef86797 \">table 7</a>)</p><p class=\"headingAnchor\" id=\"H21931978\"><span class=\"h2\">Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (daEPOCH-R)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F88411\" class=\"graphic graphic_table graphicRef88411 \">table 8</a>)</p><p class=\"headingAnchor\" id=\"H227018357\"><span class=\"h2\">Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (daEPOCH)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F105216\" class=\"graphic graphic_table graphicRef105216 \">table 9</a>)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 85686 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li><a href=\"#H4993771\" id=\"outline-link-H4993771\">INTRODUCTION</a></li><li><a href=\"#H4993783\" id=\"outline-link-H4993783\">REGIMENS</a><ul><li><a href=\"#H4994024\" id=\"outline-link-H4994024\">Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone with 21 days between cycles (R-CHOP-21)</a></li><li><a href=\"#H4994079\" id=\"outline-link-H4994079\">Rituximab plus ifosfamide, carboplatin, and etoposide (R-ICE)</a></li><li><a href=\"#H935886705\" id=\"outline-link-H935886705\">Cyclophosphamide plus doxorubicin, vincristine, and prednisone with 21 days between cycles (CHOP-21)</a></li><li><a href=\"#H935886730\" id=\"outline-link-H935886730\">Doxorubicin plus bleomycin, vinblastine, and dacarbazine (ABVD)</a></li><li><a href=\"#H4149304156\" id=\"outline-link-H4149304156\">Bendamustine plus rituximab (BR)</a></li><li><a href=\"#H546943109\" id=\"outline-link-H546943109\">Fludarabine plus rituximab (FR)</a></li><li><a href=\"#H546943159\" id=\"outline-link-H546943159\">Fludarabine, cyclophosphamide, and rituximab (FCR)</a></li><li><a href=\"#H21931978\" id=\"outline-link-H21931978\">Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (daEPOCH-R)</a></li><li><a href=\"#H227018357\" id=\"outline-link-H227018357\">Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (daEPOCH)</a></li></ul></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/85686|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/63586\" class=\"graphic graphic_table\">- R-CHOP21 regimen for non-Hodgkin lymphoma</a></li><li><a href=\"image.htm?imageKey=ONC/76030\" class=\"graphic graphic_table\">- R-ICE recipe</a></li><li><a href=\"image.htm?imageKey=ONC/81762\" class=\"graphic graphic_table\">- CHOP-21</a></li><li><a href=\"image.htm?imageKey=ONC/68131\" class=\"graphic graphic_table\">- ABVD chemotherapy for Hodgkin lymphoma</a></li><li><a href=\"image.htm?imageKey=ONC/111141\" class=\"graphic graphic_table\">- Bendamustine and rituximab for non-Hodgkin lymphoma</a></li><li><a href=\"image.htm?imageKey=ONC/86798\" class=\"graphic graphic_table\">- FR for CLL</a></li><li><a href=\"image.htm?imageKey=ONC/86797\" class=\"graphic graphic_table\">- FCR for CLL</a></li><li><a href=\"image.htm?imageKey=ONC/88411\" class=\"graphic graphic_table\">- daEPOCH-R for non-Hodgkin lymphoma</a></li><li><a href=\"image.htm?imageKey=ONC/105216\" class=\"graphic graphic_table\">- daEPOCH for non-Hodgkin lymphoma</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=initial-treatment-of-advanced-stage-iii-iv-follicular-lymphoma\" class=\"medical medical_review\">Initial treatment of advanced stage (III/IV) follicular lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-treatment-of-advanced-stage-diffuse-large-b-cell-lymphoma\" class=\"medical medical_review\">Initial treatment of advanced stage diffuse large B cell lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-treatment-of-limited-stage-i-ii-follicular-lymphoma\" class=\"medical medical_review\">Initial treatment of limited stage (I/II) follicular lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-treatment-of-limited-stage-diffuse-large-b-cell-lymphoma\" class=\"medical medical_review\">Initial treatment of limited stage diffuse large B cell lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-treatment-of-peripheral-t-cell-lymphoma\" class=\"medical medical_review\">Initial treatment of peripheral T cell lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-treatment-of-classical-hodgkin-lymphoma-in-adults\" class=\"medical medical_review\">Overview of the treatment of classical Hodgkin lymphoma in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma\" class=\"medical medical_review\">Treatment of relapsed or refractory diffuse large B cell lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-relapsed-or-refractory-follicular-lymphoma\" class=\"medical medical_review\">Treatment of relapsed or refractory follicular lymphoma</a></li></ul></div></div>","javascript":null}